Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question

被引：11

作者：

Baselga, Jose ^{[1
]}

机构：

[1] Vall Hebron Univ Hosp, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 15期

关键词：

D O I：

10.1200/JCO.2005.05.3785

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2225 / 2226

页数：2

共 20 条

[1] Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
Baselga, J
Arteaga, CL
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) : 2445 - 2459
[2] BLOOD LEAD LEVELS OF SOME CHILDREN IN NEW-SOUTH-WALES
BELL, A
[J]. MEDICAL JOURNAL OF AUSTRALIA, 1981, 1 (01) : 23 - 26
[3] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
Cappuzzo, F
Hirsch, FR
Rossi, E
Bartolini, S
Ceresoli, GL
Bemis, L
Haney, J
Witta, S
Danenberg, K
Domenichini, I
Ludovini, V
Magrini, E
Gregorc, V
Doglioni, C
Sidoni, A
Tonato, M
Franklin, WA
Crino, L
Bunn, PA
Varella-Garcia, M
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09): : 643 - 655
[4] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, TA
Wodicka, LM
Shah, NP
Velasco, AM
Fabian, MA
Treiber, DK
Milanov, ZV
Atteridge, CE
Biggs, WH
Edeen, PT
Floyd, M
Ford, JM
Grotzfeld, RM
Herrgard, S
Insko, DE
Mehta, SA
Patel, HK
Pao, W
Sawyers, CL
Varmus, H
Zarrinkar, PP
Lockhart, DJ
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) : 11011 - 11016
[5] Casado E, 2004, J CLIN ONCOL, V22, p255S
[6] Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)
Discafani, CM
Carroll, ML
Floyd, MB
Hollander, IJ
Husain, Z
Johnson, BD
Kitchen, D
May, MK
Malo, MS
Minnick, AA
Nilakantan, R
Shen, R
Wang, YF
Wissner, A
Greenberger, LM
[J]. BIOCHEMICAL PHARMACOLOGY, 1999, 57 (08) : 917 - 925
[7] Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors
Erlichman, Charles
Hidalgo, Manuel
Boni, Joseph P.
Martins, Patricia
Quinn, Susan E.
Zacharchuk, Charles
Amorusi, Peter
Adjei, Alex A.
Rowinsky, Eric K.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2252 - 2260
[8] Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
Greulich, H
Chen, TH
Feng, W
Jänne, PA
Alvarez, JV
Zappaterra, M
Bulmer, SE
Frank, DA
Hahn, WC
Sellers, WR
Meyerson, M
[J]. PLOS MEDICINE, 2005, 2 (11) : 1167 - 1176
[9] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
Kobayashi, S
Boggon, TJ
Dayaram, T
Janne, PA
Kocher, O
Meyerson, M
Johnson, BE
Eck, MJ
Tenen, DG
Halmos, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) : 786 - 792
[10] Mutations of the epidermal growth factor receptor gene in lung cancer:: Biological and clinical implications
Kosaka, T
Yatabe, Y
Endoh, H
Kuwano, H
Takahashi, T
Mitsudomi, T
[J]. CANCER RESEARCH, 2004, 64 (24) : 8919 - 8923

← 1 2 →